Bicycle therapeutics enters exclusive license and collaboration agreement with ionis to develop targeted oligonucleotide therapeutics

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that ionis pharmaceuticals has exercised its option and entered into an exclusive worldwide license and collaboration agreement for tissue-targeted delivery of oligonucleotide therapeutics using bicycles with high affinity to the transferrin recepto
BCYC Ratings Summary
BCYC Quant Ranking